TradeLink Capital LLC bought a new stake in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 28,700 shares of the biopharmaceutical company’s stock, valued at approximately $132,000. Achillion Pharmaceuticals makes up 1.2% of TradeLink Capital LLC’s portfolio, making the stock its 20th largest position.

Several other large investors have also recently bought and sold shares of ACHN. Russell Investments Group Ltd. purchased a new stake in Achillion Pharmaceuticals during the fourth quarter valued at about $162,000. Dimensional Fund Advisors LP raised its stake in Achillion Pharmaceuticals by 224.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 405,802 shares of the biopharmaceutical company’s stock valued at $1,676,000 after buying an additional 280,620 shares during the last quarter. Norges Bank purchased a new stake in Achillion Pharmaceuticals during the fourth quarter valued at about $4,623,000. Teachers Advisors LLC raised its stake in Achillion Pharmaceuticals by 23.2% in the fourth quarter. Teachers Advisors LLC now owns 943,541 shares of the biopharmaceutical company’s stock valued at $3,897,000 after buying an additional 177,537 shares during the last quarter. Finally, Creative Planning raised its stake in Achillion Pharmaceuticals by 2.0% in the first quarter. Creative Planning now owns 155,576 shares of the biopharmaceutical company’s stock valued at $655,000 after buying an additional 3,000 shares during the last quarter. 70.83% of the stock is currently owned by institutional investors and hedge funds.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) opened at 4.43 on Friday. The company’s 50 day moving average is $4.37 and its 200 day moving average is $4.12. Achillion Pharmaceuticals, Inc. has a 52-week low of $3.15 and a 52-week high of $9.49. The firm’s market cap is $605.85 million.

Achillion Pharmaceuticals (NASDAQ:ACHN) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) EPS for the quarter, hitting analysts’ consensus estimates of ($0.16). During the same quarter in the previous year, the company posted ($0.14) EPS. Equities research analysts forecast that Achillion Pharmaceuticals, Inc. will post ($0.63) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was first published by Daily Political and is the property of of Daily Political. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/08/11/tradelink-capital-llc-buys-new-stake-in-achillion-pharmaceuticals-inc-achn.html.

Several equities research analysts have recently issued reports on ACHN shares. Robert W. Baird increased their target price on shares of Achillion Pharmaceuticals from $5.00 to $10.00 and gave the stock an “outperform” rating in a research note on Monday, April 24th. Maxim Group lowered their target price on shares of Achillion Pharmaceuticals from $8.00 to $5.00 and set a “buy” rating on the stock in a research note on Tuesday, April 25th. Jefferies Group LLC reissued a “hold” rating on shares of Achillion Pharmaceuticals in a research note on Wednesday, April 26th. Zacks Investment Research lowered shares of Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, May 10th. Finally, Leerink Swann raised shares of Achillion Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $4.00 to $6.00 in a research note on Thursday, May 18th. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $8.25.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Want to see what other hedge funds are holding ACHN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN).

Institutional Ownership by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.